Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an automatic sale of 2,494 shares of common stock. The shares were sold at an average price of $69.36 per share to cover tax withholding obligations tied to recently vested restricted stock units.
These shares relate to the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. After this tax-withholding sale, Utter directly holds 70,199 shares of PTC Therapeutics common stock.
PTC Therapeutics chief financial officer Pierre Gravier reported an automatic sale of 2,992 shares of common stock at $69.36 per share. After this transaction, he holds 87,318 shares directly. The shares were sold under an irrevocable sell-to-cover instruction to satisfy tax withholding on recently vested restricted stock units (RSUs) from prior grants.
PTC Therapeutics, Inc.'s chief business officer, Eric Pauwels, reported an automatic sale of 3,019 shares of common stock in an open-market transaction at a price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding obligations upon the vesting of previously granted RSUs.
After this transaction, Pauwels directly holds 77,122 shares of PTC Therapeutics common stock. The sale reflects tax-related withholding rather than a discretionary reduction of his overall equity position.
PTC Therapeutics, Inc. reported that Chief Executive Officer Matthew B. Klein automatically sold 7,371 shares of common stock at an average price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding on the vesting of 17,500 restricted stock units from a February 15, 2025 grant of 70,000 RSUs. Following this tax-related sale, Klein owned 387,082 shares of PTC Therapeutics common stock directly.
PTC Therapeutics EVP & Chief Medical Officer Lee Scott Golden reported an automatic sale of 2,484 shares of common stock. The shares were sold on February 18, 2026 in open-market transactions at a price of $69.36 per share.
According to the filing, the sale was executed under an irrevocable "sell to cover" election to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs). After this transaction, Golden directly holds 89,944 shares of PTC Therapeutics common stock.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported automatic stock sales to cover taxes tied to restricted stock unit vesting. On February 18, he sold 3,121 shares of common stock at $69.36 per share, including 3,056 shares held directly and 65 shares held indirectly through his spouse.
These transactions were executed under irrevocable sell-to-cover elections made when the RSU grants were accepted, to satisfy tax withholding obligations. After these sales, Almstead held 112,140 shares directly and 6,726 shares indirectly through his spouse.
PTC Therapeutics executive Mark Elliott Boulding reported option exercises and share sales. On February 17, 2026, he exercised stock options for 2,813 shares of common stock at $25.69 per share, increasing his direct common stock holdings to 114,125 shares.
On February 17–18, 2026, he sold a total of 5,894 shares of common stock in open-market transactions at prices around $69.29–$70.13 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024. A portion of the shares sold was automatically sold to cover tax withholding obligations related to vesting restricted stock units. After these transactions, he directly owned 108,231 shares of common stock and 22,501 stock options that are currently exercisable.
PTC Therapeutics files its annual report describing a rare-disease portfolio in transition. The company highlights growing contributions from Sephience for phenylketonuria, which gained approvals in the EU, United States, Japan and Brazil in 2025–2026, alongside established products Emflaza, Translarna, Evrysdi royalties and AADC gene therapy Upstaza/Kebilidi.
Translarna faces a major setback after the European Commission declined to renew its conditional approval for nonsense mutation Duchenne muscular dystrophy, creating a substantial risk to related revenue, while U.S. development has been halted. Emflaza’s U.S. market now contends with generic competition following orphan exclusivity expiry for older patients.
The company deepened its neurology pipeline, including Huntington’s disease candidate votoplam, licensed to Novartis with a $1.0 billion upfront payment and potential milestones plus a U.S. profit share, and continues work on vatiquinone for Friedreich ataxia after an FDA complete response letter. PTC also monetized all remaining Evrysdi royalties, receiving total consideration of $2.1 billion, and reports 82,774,730 shares of common stock outstanding as of February 18, 2026.
PTC Therapeutics reported strong fourth quarter and full-year 2025 results and provided 2026 guidance. Full-year 2025 product and royalty revenue was $831M, exceeding guidance, helped by Sephience, which generated $92M in fourth-quarter revenue and $111M for 2025 after its 2H 2025 launch.
For 2025, total revenues were $1,730,655,000, more than doubling from $806,780,000 in 2024, based on figures presented in thousands. Net income attributable to common stockholders was $682.6M, reversing a $363.3M loss in 2024, driven largely by $998.4M of collaboration and license revenue and despite a $98.6M negative adjustment to Translarna France sales allowances.
At December 31, 2025, cash, cash equivalents and marketable securities were $1.95B, total debt was $286.6M, and total liability for sale of future royalties was $2.31B, with stockholders’ deficit at $205.3M. For full-year 2026, projected GAAP R&D and SG&A expense is $775–$815M, and projected non-GAAP R&D and SG&A is $680–$720M after excluding $95M of expected stock-based compensation.
PTCT filed a Form 144 reporting the proposed sale of 3,019 shares of common stock that vested on 02/15/2026. The filing lists the shares as arising from Restricted Stock Vesting and identifies Fidelity Brokerage Services LLC in the securities section. The excerpt also lists multiple recent sales by Mark Boulding between 01/05/2026 and 02/18/2026, including transactions of 2,266, 1,739, and 4,879 shares on specific dates with corresponding proceeds shown.